{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:54:01Z","timestamp":1793904841705,"version":"4.8.0"},"reference-count":46,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HUN-REN-SU, Human Microbiota Study Group","award":["0272"],"award-info":[{"award-number":["0272"]}]},{"name":"HUN-REN-SU, Human Microbiota Study Group","award":["952491-AmReSu"],"award-info":[{"award-number":["952491-AmReSu"]}]},{"name":"HUN-REN-SU, Human Microbiota Study Group","award":["BO\/00286\/22\/5"],"award-info":[{"award-number":["BO\/00286\/22\/5"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program","award":["0272"],"award-info":[{"award-number":["0272"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program","award":["952491-AmReSu"],"award-info":[{"award-number":["952491-AmReSu"]}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program","award":["BO\/00286\/22\/5"],"award-info":[{"award-number":["BO\/00286\/22\/5"]}]},{"name":"Janos Bolyai Scholarship","award":["0272"],"award-info":[{"award-number":["0272"]}]},{"name":"Janos Bolyai Scholarship","award":["952491-AmReSu"],"award-info":[{"award-number":["952491-AmReSu"]}]},{"name":"Janos Bolyai Scholarship","award":["BO\/00286\/22\/5"],"award-info":[{"award-number":["BO\/00286\/22\/5"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: In this study, molecular mechanisms contributing to delafloxacin resistance in Pseudomonas aeruginosa strains were investigated. Delafloxacin is a recently approved fluoroquinolone currently introduced to clinical applications. Methods: A total of 52 P. aeruginosa strains were collected from clinical isolates. Antimicrobial susceptibility testing was performed via broth microdilution, and the minimum inhibitory concentration (MIC) values for ciprofloxacin, levofloxacin, delafloxacin, ceftazidime and imipenem were determined. Five delafloxacin-resistant P. aeruginosa strains were selected for whole-genome sequencing (WGS). Results: MIC50 values were determined, and the following results were obtained: ciprofloxacin 0.25 mg\/L, levofloxacin 0.25 mg\/L and delafloxacin 1 mg\/L. All five selected strains showed both extended-spectrum beta-lactamase and carbapenemase production. WGS analysis of these strains determined the sequence types (STs), namely, ST235 (two strains), ST316 (two strains) and ST395. Several mutations in quinolone-resistance-determining regions (QRDRs) were detected in all five delafloxacin-resistant P. aeruginosa strains as follows: gyrA Thr83Ile and parC Ser87Leu mutations were present in all five strains, while parE Thr223Ala in ST235, Glu459Val in ST316 and Val200Met in ST395 were detected. MexAB-OprM and MexCD-OprJ efflux pumps were uniformly present in all delafloxacin-resistant P. aeruginosa strains. All strains of ST235 and ST316 carried blaNDM-1 in combination with other beta-lactamases. In our study, the in vitro efficacy of delafloxacin is inferior compared to previous fluoroquinolones based on MIC50 values; however, MIC values of delafloxacin ranged between 0.125 and 128 mg\/L in our P. aeruginosa collection, and 21 out of 52 strains showed susceptibility to delafloxacin. Conclusions: Multiple QRDR mutations combined with several efflux pumps confer delafloxacin resistance in P. aeruginosa. Among the different detected multidrug-resistant P. aeruginosa strains in this study, we also report on an NDM-1 producing P. aeruginosa ST316 in Hungary.<\/jats:p>","DOI":"10.3390\/antibiotics14060542","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T20:26:50Z","timestamp":1748204810000},"page":"542","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Variable In Vitro Efficacy of Delafloxacin on Multidrug-Resistant Pseudomonas aeruginosa and the Detection of Delafloxacin Resistance Determinants"],"prefix":"10.3390","volume":"14","author":[{"given":"Andr\u00e1s","family":"Kubicsk\u00f3","sequence":"first","affiliation":[{"name":"Institute of Medical Microbiology, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Kamotsay","sequence":"additional","affiliation":[{"name":"Central Microbiology Laboratory, National Institute of Hematology and Infectious Disease, Central Hospital of Southern-Pest, 1097 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Banczerowski","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neurointervention, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Sipos","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neurointervention, Semmelweis University, 1085 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f3ra","family":"Szab\u00f3","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology, Semmelweis University, 1089 Budapest, Hungary"},{"name":"Department of Neurosurgery and Neurointervention, Semmelweis University, 1085 Budapest, Hungary"},{"name":"HUN-REN-SU Human Microbiota Research Group, 1052 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7067-7055","authenticated-orcid":false,"given":"B\u00e9la","family":"Kocsis","sequence":"additional","affiliation":[{"name":"Institute of Medical Microbiology, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cmi.2023.12.026","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: Update from ESGARS-ESCMID\/ISARPAE Group","volume":"30","author":"Oliver","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13756-018-0370-9","article-title":"Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: A systematic review and meta-analysis","volume":"7","author":"Raman","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Palavutitotai, N., Jitmuang, A., Tongsai, S., Kiratisin, P., and Angkasekwinai, N. (2018). Epidemiology and risk factors of extensively drug-resistant Pseudomonas aeruginosa infections. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0193431"},{"key":"ref_4","first-page":"mgen000513","article-title":"From genotype to phenotype: Adaptations of Pseudomonas aeruginosa to the cystic fibrosis environment","volume":"7","author":"Camus","year":"2021","journal-title":"Microb. Genom."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"De Oliveira, D.M.P., Forde, B.M., Kidd, T.J., Harris, P.N.A., Schembri, M.A., Beatson, S.A., Paterson, D.L., and Walker, M.J. (2020). Antimicrobial Resistance in ESKAPE Pathogens. Clin. Microbiol. Rev., 33.","DOI":"10.1128\/CMR.00181-19"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1556\/030.2024.02352","article-title":"ESKAPE pathogens in pediatric cardiac surgery patients: 5-year microbiological monitoring in a tertiary hospital in Kazakhstan","volume":"71","author":"Baigenzhin","year":"2024","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Jurado-Mart\u00edn, I., Sainz-Mej\u00edas, M., and McClean, S. (2021). Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063128"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Horcajada, J.P., Montero, M., Oliver, A., Sorl\u00ed, L., Luque, S., G\u00f3mez-Zorrilla, S., Benito, N., and Grau, S. (2019). Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin. Microbiol. Rev., 32.","DOI":"10.1128\/CMR.00031-19"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lorusso, A.B., Carrara, J.A., Barroso, C.D.N., Tuon, F.F., and Faoro, H. (2022). Role of Efflux Pumps on Antimicrobial Resistance in Pseudomonas aeruginosa. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415779"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Thi, M.T.T., Wibowo, D., and Rehm, B.H.A. (2020). Pseudomonas aeruginosa Biofilms. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228671"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Karruli, A., Catalini, C., D\u2019amore, C., Foglia, F., Mari, F., Harxhi, A., Galdiero, M., and Durante-Mangoni, E. (2023). Evidence-Based Treatment of Pseudomonas aeruginosa Infections: A Critical Reappraisal. Antibiotics, 12.","DOI":"10.3390\/antibiotics12020399"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Reid, E., Walters, R.W., and Destache, C.J. (2021). Beta-Lactam vs. Fluoroquinolone Monotherapy for Pseudomonas aeruginosa Infection: A Systematic Review and Meta-Analysis. Antibiotics, 10.","DOI":"10.21203\/rs.3.rs-379835\/v1"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Matarac\u0131 Kara, E., \u00c7akmak, S.M., and Er, S. (2024). Assessment of in vitro interactions between delafloxacin and other antimicrobials against multi-drug resistant Pseudomonas aeruginosa strains. J. Chemother., 1\u20137.","DOI":"10.1080\/1120009X.2024.2445910"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40121-022-00591-2","article-title":"Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa","volume":"11","author":"Holger","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jones, F., Hu, Y., and Coates, A. (2022). The Efficacy of Using Combination Therapy against Multi-Drug and Extensively Drug-Resistant Pseudomonas aeruginosa in Clinical Settings. Antibiotics, 11.","DOI":"10.3390\/antibiotics11030323"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-0042-1742636","article-title":"Plasmid-Mediated Fluoroquinolone Resistance in Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"14","author":"Venkataramana","year":"2022","journal-title":"J. Lab. Physicians"},{"key":"ref_17","first-page":"214","article-title":"QRDR mutations, efflux system & antimicrobial resistance genes in enterotoxigenic Escherichia coli isolated from an outbreak of diarrhoea in Ahmedabad, India","volume":"134","author":"Pazhani","year":"2011","journal-title":"Indian. J. Med. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1093\/infdis\/jiw299","article-title":"Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections","volume":"215","author":"Juan","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1556\/030.2024.02309","article-title":"Genomic insights into NDM-1-producing Pseudomonas aeruginosa: Current status in a Bulgarian tertiary hospital and on the Balkans","volume":"71","author":"Strateva","year":"2024","journal-title":"Acta Microbiol. Immunol. Hung."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","article-title":"Carbapenemase-producing Pseudomonas aeruginosa\u2014An emerging challenge","volume":"11","author":"Tenover","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"ref_21","unstructured":"(2024). WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance, World Health Organization."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41429-020-0291-8","article-title":"Antibiotics in the clinical pipeline in October 2019","volume":"73","author":"Butler","year":"2020","journal-title":"J. Antibiot."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical review of delafloxacin: A novel anionic fluoroquinolone","volume":"73","author":"Mogle","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kocsis, B., Guly\u00e1s, D., and Szab\u00f3, D. (2021). Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121506"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Craddock, V.D., Steere, E.L., Harman, H., and Britt, N.S. (2023). Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Cystic Fibrosis Sputum Model. Antibiotics, 12.","DOI":"10.3390\/antibiotics12061078"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14787210.2018.1489721","article-title":"Delafloxacin: A novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa","volume":"16","author":"Ocheretyaner","year":"2018","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1080\/14656566.2021.1957098","article-title":"Delafloxacin as a treatment option for community-acquired pneumonia infection","volume":"22","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cmi.2023.12.008","article-title":"In vitro susceptibility to delafloxacin of Pseudomonas aeruginosa with resistance to other quinolones (ciprofloxacin and levofloxacin)","volume":"30","author":"Santotoribio","year":"2024","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"106196","DOI":"10.1016\/j.ijantimicag.2020.106196","article-title":"Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired \u03b2-lactamases: 2020 update","volume":"56","author":"Oliver","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/22221751.2020.1713025","article-title":"Co-existence of OXA-48 and NDM-1 in colistin resistant Pseudomonas aeruginosa ST235","volume":"9","author":"Vatansever","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_31","first-page":"18","article-title":"Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis","volume":"27","author":"Lee","year":"2018","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.cmi.2017.06.018","article-title":"Global emergence of the widespread Pseudomonas aeruginosa ST235 clone","volume":"24","author":"Treepong","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ijantimicag.2019.08.003","article-title":"Epidemiology and characterisation of carbapenem-non-susceptible Pseudomonas aeruginosa in a large intensive care unit in Jakarta, Indonesia","volume":"54","author":"Saharman","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_34","first-page":"mgen000989","article-title":"Dissecting the genotypic features of a fluoroquinolone-resistant Pseudomonas aeruginosa ST316 sublineage causing ear infections in Shanghai, China","volume":"9","author":"Sun","year":"2023","journal-title":"Microb. Genom."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1099\/jmm.0.000730","article-title":"Identification of carbapenem-resistant Pseudomonas aeruginosa in selected hospitals of the Gulf Cooperation Council States: Dominance of high-risk clones in the region","volume":"67","author":"Zowawi","year":"2018","journal-title":"J. Med. Microbiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1128\/JCM.00102-11","article-title":"Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types","volume":"49","author":"Cholley","year":"2011","journal-title":"J. Clin. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e006278","DOI":"10.1136\/bmjopen-2014-006278","article-title":"Seeking the source of Pseudomonas aeruginosa infections in a recently opened hospital: An observational study using whole-genome sequencing","volume":"4","author":"Quick","year":"2014","journal-title":"BMJ Open"},{"key":"ref_38","first-page":"e000129","article-title":"Genomic characterization of a local epidemic Pseudomonas aeruginosa reveals specific features of the widespread clone ST395","volume":"3","author":"Petitjean","year":"2017","journal-title":"Microb. Genom."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Bolanos, S., Acebes, C., Martinez-Exposito, \u00d3., Boga, J.A., Fernandez, J., and Rodriguez-Lucas, C. (2024). Role of parC Mutations at Position 84 on High-Level Delafloxacin Resistance in Methicillin-Resistant Staphylococcus aureus. Antibiotics, 13.","DOI":"10.3390\/antibiotics13070641"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1093\/jac\/dkae269","article-title":"In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates","volume":"79","author":"Luzarraga","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Guly\u00e1s, D., Kamotsay, K., Szab\u00f3, D., and Kocsis, B. (2023). Investigation of Delafloxacin Resistance in Multidrug-Resistant Escherichia coli Strains and the Detection of E. coli ST43 International High-Risk Clone. Microorganisms, 11.","DOI":"10.3390\/microorganisms11061602"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kubicsk\u00f3, A., Kamotsay, K., Szab\u00f3, D., and Kocsis, B. (2024). Analysis of molecular mechanisms of delafloxacin resistance in Escherichia coli. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-78124-9"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kubicsk\u00f3, A., Juh\u00e1sz, J., Kamotsay, K., Szabo, D., and Kocsis, B. (2025). Detection of Delafloxacin Resistance Mechanisms in Multidrug-Resistant Klebsiella pneumoniae. Antibiotics, 14.","DOI":"10.3390\/antibiotics14010062"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Fuzi, M., Szabo, D., and Csercsik, R. (2017). Double-Serine Fluoroquinolone Resistance Mutations Advance Major International Clones and Lineages of Various Multi-Drug Resistant Bacteria. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.02261"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jac\/dkab421","article-title":"Bicarbonate modulates delafloxacin activity against MDR Staphylococcus aureus and Pseudomonas aeruginosa","volume":"77","author":"Holland","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/crj.13262","article-title":"Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis","volume":"15","author":"Millar","year":"2021","journal-title":"Clin. Respir. J."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/6\/542\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:40:01Z","timestamp":1760031601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/6\/542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,25]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["antibiotics14060542"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14060542","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,25]]}}}